Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.

Cancer discovery - 1 Aug 2015

Ma Patrick C

Abstract excerpt

Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal METex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Alternative Splicing
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 26243862
DOI: 10.1158/2159-8290.CD-15-0769
PMCID: PMC4617658

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.PMID 26243862Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Semantic proximity Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domainSemantic proximity Read ↗

Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.Semantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

Gastrointestinal malignancies harbor actionable MET exon 14 deletionsSemantic proximity Read ↗

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Semantic proximity Read ↗

MET fusions are targetable genomic variants in the treatment of advanced malignancies.Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.